Clinical trial NCT05629689: A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
Official title: A Phase 1a/1b, Multi-Centre, Open-Label, Dose-Escalation and Dose-Expansion Study in Patients With Solid Tumour Malignancies to Evaluate GEH200520 Injection / GEH200521 (18F) Injection Safety and Tolerability, PET Imaging, Pharmacokinetics, and Changes in Imaging After Treatment
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Malignant Solid Tumor
Oncology
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
First posted: 2022-11-29
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days.

Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment.

Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunotherapy immune-checkpoint inhibitor (ICI) treatment visits and 2 additional imaging and 1 follow-up visit . The estimated duration of Part B is approximately 64 days.


Eligibility criteria: Inclusion Criteria:

* The subject is able and willing to comply with all study procedures as described in the protocol, including the imaging day pre-visit requirements, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
* The subject is male or female, ≥18 years of age.
* Subject has a life expectancy ≥12 weeks.
* Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
* Subject has an irresectable or metastatic solid tumour or a local and resectable head and neck squamous cell carcinoma.
* Subject is eligible for ICI treatment.
* Subject is male, or a female who agrees to comply with the protocol contraception method.

Exclusion Criteria:

* Subject is unable to undergo all procedures in the study and/or is unable to remain still and tolerate the imaging procedure.
* Subject has 12-lead ECG significant findings during screening, per Investigator's assessment.
* Subject is not stable due to medical condition or therapy that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
* Subject has active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents.
* Subject has any safety laboratory test results (clinical chemistry, haematology, and urinalysis) that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
* Subject is pregnant or planning to become pregnant or is lactating.
* Subject has a history of alcohol or drug abuse within the last year.

Primary outcomes:
measure: Part A: The incidence of AEs upon causality to the IMPs.
timeFrame: Part A: 7 days
measure: Part A: The severity of AEs per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0) upon causality to the IMPs.
timeFrame: Part A: 7 days
measure: To evaluate the time-course changes in GEH200521 (18F) Injection uptake after immune-checkpoint inhibitor (ICI) treatment cycles compared to baseline.
timeFrame: Part B: 50 days
Secondary outcomes:
measure: To evaluate the radiation dosimetry of a fixed dose of GEH200521 (18F) Injection when administered with the different GEH200520 Injection mass doses by cumulated activity in source regions and by entire body.
timeFrame: 7 days
measure: To evaluate the optimal imaging time window for GEH200521 (18F) Injection positron emission tomography (PET) imaging when administered with different GEH200520 Injection mass doses for Part A subjects.
timeFrame: 7 days
measure: To determine the appropriate mass dose of GEH200520 Injection for administration with GEH200521 (18F) Injection to achieve an acceptable PET image quality for Part A subjects.
timeFrame: 7 days
measure: To characterize the pharmacokinetic (PK) properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
timeFrame: 7 days
measure: To characterize the pharmacokinetic (PK) properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
timeFrame: 7 days
measure: To characterize the pharmacokinetic (PK) properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
timeFrame: 7 days
measure: To characterize the pharmacokinetic (PK) properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
timeFrame: 7 days
measure: To characterize the pharmacokinetic (PK) properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
timeFrame: 7 days
measure: Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs, for Part A subjects.
timeFrame: 7 days
measure: Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part A subjects
timeFrame: Baseline, 24 hours, 7 days post IMP administration
measure: Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
timeFrame: Baseline, 24 hours, 7 days post IMP administration
measure: Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
timeFrame: Baseline, 24 hours, 7 days post IMP administration
measure: Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part A subjects
timeFrame: Baseline, 2 hours, 24 hours, 7 days post IMP administration
measure: Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part A subjects
timeFrame: Baseline, 2 hours, 24 hours, 7 days post IMP administration
measure: Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part A subjects
timeFrame: Baseline, 2 hours, 24 hours, 7 days post IMP administration
measure: Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part A subjects
timeFrame: Baseline, 2 hours, 24 hours, 7 days post IMP administration
measure: To assess immunogenicity, via the incidence of treatment-induced anti-drug antibodies responses, after a single injection of the different GEH200520 Injection mass doses administered with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
timeFrame: 7 days
measure: Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs
timeFrame: 50 days
measure: To assess the biodistribution and tumour uptake of GEH200521 (18F) Injection with the optimal GEH200520 Injection dose determined in Part A based on quantitative measurements of GEH200521 (18F) in regions of interest for Part B subjects.
timeFrame: 50 days
measure: To assess the relationship between tumour GEH200521 (18F) Injection uptake (SUV value) and immune cell CD8+ expression score from a biopsy sample/resected lesion when available based on IHC results for Part B subjects.
timeFrame: 50 days
measure: To compare changes in tumour GEH200521 (18F) Injection uptake with changes in computed tomography (CT) image assessment, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for Part B subjects when available .
timeFrame: 50 days
measure: To compare changes in tumour GEH200521 (18F) Injection uptake with changes in computed tomography (CT) image assessment, according to [18F]-fluorodeoxyglucose (FDG) scans, when available for Part B subjects.
timeFrame: 50 days
measure: Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part B subjects
timeFrame: Baseline, Day 15, Day 36, Day 50
measure: Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
timeFrame: Baseline, Day 15, Day 36, Day 50
measure: Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
timeFrame: Baseline, Day 15, Day 36, Day 50
measure: Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part B subjects
timeFrame: Baseline, Day 15, Day 36, Day 50
measure: Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part B subjects
timeFrame: Baseline, Day 15, Day 36, Day 50
measure: Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part B subjects
timeFrame: Baseline, Day 15, Day 36, Day 50
measure: Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part B subjects
timeFrame: Baseline, Day 15, Day 36, Day 50
measure: To characterize the PK properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
timeFrame: 50 days
measure: To characterize the PK properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
timeFrame: 50 days
measure: To characterize the PK properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
timeFrame: 50 days
measure: To characterize the PK properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
timeFrame: 50 days
measure: To characterize the PK properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
timeFrame: 50 days
measure: To compare immunogenicity, via the incidence of treatment-induced anti-drug antibodies responses, after multiple administrations of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
timeFrame: 50 days
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: UMC Groningen
Study officials:
affiliation: GE Healthcare
name: Yaron Raiter, MD
role: STUDY_DIRECTOR
References: